As reported by Legal Dealmaker on January 13, the US fund signed the acquisition of the Spanish company, a world leader in infertility treatments, eleven months after the transaction was announced, according to financial sources. The private equity giant committed to pay €3 billion.
Valencia-based IVIRMA Global is the world’s premier fertility group that leads the industry in research, success rates and patient care. From clinical excellence, to research and innovation, to teaching the next generation of reproductive endocrinologists, to advancing cutting edge protocols, standards and practices in the field.
The deal completion has been delayed for almost a year. On the one hand, IVIRMA and KKR have been negotiating the final details of the deal for months. On the other hand, it was not until 21 December that the National Markets and Competition Commission (CNMC) authorised the transaction, albeit with conditions.
Freshfields advised KKR with a team formed by partners Álvaro Iza and Armando Albarrán, counsel Enrique Carrera senior associates Álvaro Puig García-Gango and Carla Gómez Crespo, and associates Iciar Herrero Montañés, Javier Fernández Hinojal, Laura Cue López and Mario Pacini.
Linklaters Spain advised IVIRMA´s shareholders with a Corporate team made up of partner Carmen Burgos, managing associate José Buigues, associate Celso Méndez, and junior associates Sofía Maldonado and Andrea García. The deal also counted on the advice of a Tax team including managing associate Álvaro Albiñana, a Competition team formed by consultant Juan Passás and associate Barbara Rivera, a Public Law team including lawyer Sergio García and a Labour team with counsel Moira Guitart.
Garrigues advised the seller´s shareholders with a team comprising partners Francisco Soler Caballero, Lorena Colomer Romero and Alejandro Micó Llorens.
Andersen advised the seller´s shareholders with a team made up of partners Ignacio Aparicio Ramos and María Olleros Sánchez.
